Biohaven Pharmaceutical Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Biohaven Pharmaceutical stock.
View analyst ratings for Biohaven Pharmaceutical or view top-rated stocks.

Wall Street analysts have given Biohaven Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biohaven Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Biohaven Pharmaceutical.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) posted its earnings results on Sunday, February, 28th. The company reported ($3.62) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.89) by $0.73. The company had revenue of $35.10 million for the quarter, compared to the consensus estimate of $35.01 million. The company's quarterly revenue was up 350900.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($2.85) EPS.
View Biohaven Pharmaceutical's earnings history.

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BHVN stock has increased by 112.9% and is now trading at $84.03.
View which stocks have been most impacted by COVID-19.

Biohaven Pharmaceutical issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $35-35 million, compared to the consensus revenue estimate of $25.31 million.

11 analysts have issued 12-month price objectives for Biohaven Pharmaceutical's shares. Their forecasts range from $41.00 to $120.00. On average, they expect Biohaven Pharmaceutical's stock price to reach $95.30 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price.
View analysts' price targets for Biohaven Pharmaceutical or view top-rated stocks among Wall Street analysts.

Some companies that are related to Biohaven Pharmaceutical include Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), UCB (UCBJF), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), CureVac (CVAC), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA) and Grifols (GRFS).
View all of BHVN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.88%), Stifel Financial Corp (4.24%), Alliancebernstein L.P. (2.01%), Wells Fargo & Company MN (1.67%), Brown Advisory Inc. (1.48%) and Bank of New York Mellon Corp (1.35%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, Robert Berman, Vlad Coric and William A Jones Jr.
View institutional ownership trends for Biohaven Pharmaceutical.

BHVN stock was sold by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Alliancebernstein L.P., Columbus Circle Investors, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Candriam Luxembourg S.C.A., Rhenman & Partners Asset Management AB, and Wells Fargo & Company MN. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, Robert Berman, and William A Jones Jr.
View insider buying and selling activity for Biohaven Pharmaceutical or view top insider-selling stocks.

BHVN stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Clearbridge Investments LLC, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Morgan Stanley, BlackRock Inc., International Biotechnology Trust PLC, and Brown Advisory Inc.. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric.
View insider buying and selling activity for Biohaven Pharmaceutical or or view top insider-buying stocks.

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BHVN stock can currently be purchased for approximately $84.03.

Biohaven Pharmaceutical has a market capitalization of $5.04 billion. The company earns $-528,800,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis.

Biohaven Pharmaceutical employs 647 workers across the globe.

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

Biohaven Pharmaceutical is headquartered at 215 CHURCH STREET, NEW HAVEN CT, 06510.

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.